In a 75-year-old man with hypertension, stage 3 chronic kidney disease, and gout on allopurinol who presents with acute right knee pain after spinal fusion and synovial fluid showing negatively birefringent crystals without bacteria, what is the best treatment for his joint pain?

Intra-articular corticosteroids are the best treatment for this patient's acute gout flare

Given this patient's stage 3 CKD (creatinine 1.90 mg/dL), recent major surgery, and acute gout flare, intra-articular corticosteroids (Option C) represent the optimal choice for managing his joint pain.

Clinical Reasoning

This is a straightforward case of acute gout (confirmed by negatively birefringent crystals on synovial fluid analysis) in a patient with significant contraindications to other standard therapies:

Why Intra-articular Corticosteroids (Option C)?

The 2017 ACP guidelines strongly recommend corticosteroids, NSAIDs, or colchicine for acute gout 1. However, the route and specific agent matter critically in this clinical context:

• Corticosteroids are recommended as first-line therapy in patients with contraindications to other agents 1
• Intra-articular administration provides direct anti-inflammatory effect at the affected joint while minimizing systemic exposure
• This is particularly advantageous in a post-surgical patient where systemic immunosuppression should be minimized
• The monoarticular presentation (single knee joint) makes this route ideal

Why NOT the Other Options?

Option A (Stop allopurinol): This is incorrect and potentially harmful. The 2020 ACR guidelines explicitly state that urate-lowering therapy should NOT be stopped during an acute flare 2. The FDA label confirms that acute flares commonly occur during early allopurinol therapy and recommends continuing the drug while adding anti-inflammatory prophylaxis 3. Stopping allopurinol would cause serum urate fluctuations that could worsen and prolong the flare.

Option B (Intravenous ceftriaxone): The Gram stain showed no bacteria, and the synovial fluid WBC count of 4,000/µL is consistent with crystal arthropathy rather than septic arthritis (which typically shows >50,000/µL). Antibiotics are not indicated.

Option D (Oral colchicine): While colchicine is effective for acute gout 1, this patient has stage 3 CKD with creatinine 1.90 mg/dL. Colchicine toxicity is significantly increased in CKD, and the drug requires dose reduction based on renal function 4. The FDA label specifically contraindicates colchicine in patients with renal impairment who are using certain medications. Given the recent surgery and potential for drug interactions, plus the increased risk of gastrointestinal toxicity (diarrhea, nausea, vomiting) in a post-operative patient, colchicine is suboptimal here.

Key Clinical Considerations

Regarding Allopurinol Management

• Continue the allopurinol at the current dose 2, 3
• The serum uric acid of 5.5 mg/dL indicates the allopurinol is working (target <6 mg/dL)
• Acute flares during allopurinol therapy are expected and do not indicate treatment failure
• The 2020 ACR guidelines strongly recommend prophylactic anti-inflammatory therapy for 3-6 months when on urate-lowering therapy 2

Post-Surgical Context

This patient is one day post-spinal fusion, which adds important considerations:

• Systemic NSAIDs are contraindicated due to CKD and increased bleeding risk post-operatively
• Systemic corticosteroids carry infection risk in the immediate post-operative period
• Intra-articular injection provides localized treatment without these systemic risks

Common Pitfalls to Avoid

1. Do not stop allopurinol during an acute flare - this is a common error that worsens outcomes
2. Do not use full-dose colchicine in CKD - toxicity risk is substantially elevated
3. Do not assume infection without appropriate synovial fluid findings - crystal arthritis can present dramatically but doesn't require antibiotics

Follow-up Management

After treating this acute flare, ensure the patient receives:

• Prophylactic anti-inflammatory therapy (low-dose colchicine 0.6 mg daily if tolerated with renal dosing, or low-dose prednisone) for at least 3-6 months while continuing allopurinol 2, 1
• This prevents recurrent flares during the urate mobilization phase

2, 1, 3, 4